A study funded by the Hass Avocado Board by the researchers at Louisiana State University, the United States shows a body weight loss and reduction in risk of heart diseases with the consumption of avocados. Avocado fruit weighs between 220 grams and 1.4 kg (or between eight ounces and three pounds). The researchers conducted studies among 30,000 individuals with the consumption of avocados. Their study results show following health benefits of the consumption avocado when compared with non-consumers of avocado.
Researchers say avocados contains essential nutrients such as minerals (magnesium, folate, potassium and copper), vitamin E and vitamin C, fiber and healthy fats. Consumption of avocados results in better health parameters for an individual and should be part of healthy lifestyle. Avocados contain oleic acid, which is a monounsaturated fat. Olive oil also contains the same fat. Most of the calories (77 percent) come from oleic acid in avocados. Earlier studies show avocados are associated with lower risk of heart diseases, inflammation, anti-aging and cancer. Author of the study was Dr. Carol O'Neil, from Louisiana State University, the United States and the study findings were published in the journal Internal Medicine Review.
A study by researchers shows risk reduction to cardiovascular events associated with a high-fat diet with the consumption of cinnamon. Animal studies with cinnamon show slowdown in the fat storing process of the body as cinnamon activate anti-inflammatory and antioxidant systems of the body. The researchers conducted an experiment with rat models for 12 weeks duration. Researchers found following healthy health factors in those rat models fed with a high-fat diet along with cinnamon supplements when compared with rat models fed with a high-fat diet but without cinnamon supplements.
Earlier studies show cinnamon association with the improvement in hippocampus part of the brain. Hippocampus part in the brain is associated with memory function of an individual. The study findings were presented in the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology.
Imeglimin is an oral anti-diabetic and an experimental drug being developed by Poxel. This drug is intended to restore normal insulin secretion, improve glucose uptake of muscles and prevents hepatic gluconeogenesis (GNG). A phase 2B trial of imeglimin has met its primary endpoint and the company is going to conduct phase 3 trials by the end of 2017 after meeting Japanese regulators. Japanese investigators have conducted trials of 299 diabetes patients. Trials results show imeglimin is better than placebo in reducing glycated hemoglobin A1c, which shows 3-month average glucose levels of an individual.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.